Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) have been given an average rating of “Hold” by the fourteen analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $46.64.
IONS has been the subject of a number of analyst reports. BMO Capital Markets lowered their price target on shares of Ionis Pharmaceuticals from $70.00 to $67.00 and set an “outperform” rating for the company in a report on Thursday, February 23rd. Morgan Stanley lifted their price objective on shares of Ionis Pharmaceuticals from $40.00 to $42.00 and gave the company an “equal weight” rating in a report on Tuesday, April 11th. StockNews.com initiated coverage on Ionis Pharmaceuticals in a research note on Thursday. They issued a “hold” rating on the stock. Citigroup upgraded Ionis Pharmaceuticals from a “sell” rating to a “neutral” rating and raised their price target for the company from $30.00 to $36.00 in a research note on Thursday, May 4th. Finally, Sanford C. Bernstein began coverage on shares of Ionis Pharmaceuticals in a research report on Tuesday, March 21st. They set an “underperform” rating and a $31.00 target price on the stock.
Institutional Trading of Ionis Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Captrust Financial Advisors increased its stake in shares of Ionis Pharmaceuticals by 21.1% during the 2nd quarter. Captrust Financial Advisors now owns 1,429 shares of the company’s stock valued at $53,000 after acquiring an additional 249 shares during the last quarter. Lincoln National Corp boosted its stake in Ionis Pharmaceuticals by 2.1% in the fourth quarter. Lincoln National Corp now owns 13,099 shares of the company’s stock valued at $495,000 after acquiring an additional 269 shares during the period. Delphia USA Inc. raised its holdings in shares of Ionis Pharmaceuticals by 3.1% during the third quarter. Delphia USA Inc. now owns 9,597 shares of the company’s stock valued at $424,000 after buying an additional 286 shares during the last quarter. Commerce Bank increased its stake in Ionis Pharmaceuticals by 4.2% during the 4th quarter. Commerce Bank now owns 7,742 shares of the company’s stock valued at $292,000 after buying an additional 311 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in Ionis Pharmaceuticals by 7.1% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,708 shares of the company’s stock worth $208,000 after buying an additional 314 shares in the last quarter. 87.32% of the stock is owned by hedge funds and other institutional investors.
Ionis Pharmaceuticals Stock Up 0.9 %
Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) last released its quarterly earnings results on Wednesday, May 3rd. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.13. Ionis Pharmaceuticals had a negative net margin of 56.85% and a negative return on equity of 57.58%. The business had revenue of $131.00 million for the quarter, compared to the consensus estimate of $126.88 million. During the same period last year, the firm earned ($0.46) earnings per share. The company’s quarterly revenue was down 7.7% on a year-over-year basis. Equities research analysts forecast that Ionis Pharmaceuticals will post -3.57 earnings per share for the current year.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T.
See Also
- Get a free copy of the StockNews.com research report on Ionis Pharmaceuticals (IONS)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
